• SearchField_GetLegal

Aranesp

AranespAranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.

The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:

  • Myocardial infarction, or heart attack, as well as congestive heart failure
  • Hypertension (high blood pressure), with increased risk of stroke
  • Venous thromboembolism
  • Thrombosis of vascular access
  • Tumor progression or recurrence

If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.

Connect with Top-rated Attorneys Near You

    Latest Article

      GETLEGAL®ATTORNEY DIRECTORY

      Find Leading Attorneys in Your Area

          NEED PROFESSIONAL HELP?

          Talk to an Attorney

          How It Works

          • Briefly tell us about your case
          • Provide your contact information
          • Choose attorneys to contact you
          • SearchField_GetLegal

          ABOUT GETLEGAL

          Our mission at GetLegal is to develop a family of sites that constitute the most useful, informative, reliable and exciting collection of legal resources on the web. We are constantly working to expand and improve many resources we offer to legal professionals and the public.

          Contact Us : 817-359-7077

          RECENT TWEETS

          NEWSLETTER SIGN-UP

          By submitting information to this site, you give permission to GetLegal, or a partner of GetLegal, to contact you by email.

          Advertise With Us

          © 2008-2021 LawConnect, Inc. All rights reserved. Sitemap | Copyright/DMCA Policy | Privacy Policy | Terms of Use | Disclosures/Disclaimers